(R)-3-(1-氨基乙基)苯甲酸

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (R)-3-(1-氨基乙基)苯甲酸
• 英文名称: 3-[(1R)-1-azaniumylethyl]benzoate
• 化学式: C9H11NO2
• 分子量: 165.19
• InChiKey: NSRCJWRFTUMEEL-ZCFIWIBFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS
  申请人：PFIZER INC.

  公开号：US20150259323A1

  公开（公告）日：2015-09-17

  Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

  本文描述了抑制二酰基甘油酰基转移酶2（DGAT2）活性的化合物I的使用，以及它们在治疗相关动物疾病中的用途。
• Diacylglycerol acyltransferase 2 inhibitors
  申请人：Pfizer Inc.

  公开号：US10188653B2

  公开（公告）日：2019-01-29

  Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

  本文描述了抑制二酰甘油酰基转移酶 2（DGAT2）活性的式 I 化合物及其在治疗动物相关疾病中的用途。
• Method of identifying inhibitors of CDC25
  申请人：——

  公开号：US20020183249A1

  公开（公告）日：2002-12-05

  The present invention relates to polypeptides which comprise the ligand binding domain of Cdc25, crystalline forms of these polypeptides and the use of these crystalline forms to determine the three dimensional structure of the catalytic domain of Cdc25. The invention also relates to the use of the three dimensional structure of the Cdc25 catalytic domain in methods of designing and/or identifying potential inhibitors of Cdc25 activity, for example, compounds which inhibit the binding of a native substrate to the Cdc25 catalytic domain.

  本发明涉及包含 Cdc25 配体结合结构域的多肽、这些多肽的结晶形式以及利用这些结晶形式确定 Cdc25 催化结构域的三维结构。本发明还涉及将 Cdc25 催化结构域的三维结构用于设计和/或鉴定 Cdc25 活性的潜在抑制剂的方法，例如，抑制原生底物与 Cdc25 催化结构域结合的化合物。
• DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC AND RELATED DISORDERS
  申请人：Pfizer Inc.

  公开号：EP3119757B1

  公开（公告）日：2018-05-16
• DIPEPTIDYL PEPTIDASE-IV INHIBITORS
  申请人：Kroth Heiko

  公开号：US20100009961A1

  公开（公告）日：2010-01-14

  The present invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitor compounds. The present invention also provides synthetic methods for preparation of such compounds, methods of inhibiting DPP-IV using such compounds and pharmaceutical formulations containing them for treatment of DPP-IV mediated diseases, in particular, Type-2 diabetes.